Gynecologic Cancer
11 cases on ovarian cancer maintenance and sequencing decisions, cervical cancer therapy selection, endometrial cancer biomarker-directed therapy, hereditary-risk surgical timing, and gestational trophoblastic neoplasia risk scoring — choose a case below to open its full multi-voice debate.
Diane R., 58, a retired chemistry teacher who spends her mornings restoring stained-glass panels for a county-fair co-op, 23 months into a complete response on maintenance therapy. The disagreement is whether a trial's own arbitrary stopping point still applies to a patient the trial never actually studied past that date.
Carol T., 66, who moved in with her sister after her husband died and now drives her to appointments neither much enjoys. The disagreement comes down to one scan read two different ways, and which of a trial's two separate exclusion criteria that reading actually falls under.
Priya M., who took up half-marathon training during her first round of chemotherapy and has kept it through two relapses since. The disagreement is what to make of two drugs in the same class landing on opposite sides of their own trials.
Renata S., 31, whose younger sister moved into her spare room the week of her diagnosis to help with a two-year-old. The disagreement is left genuinely open between an intention-to-treat benefit reading and a real caution about an underpowered subgroup.
Angela K., 36, five months into finalizing the adoption of two siblings she and her wife have fostered for two years. The disagreement is over the timing and sequence of two real trials' worth of evidence, not whether treatment happens at all.
Dolores V., 63, who has run the same small bakery on the same corner for twenty-two years and closed it only twice. The disagreement is which of two similar-looking trials' survival maturity should actually decide between two checkpoint inhibitors nobody has tested head-to-head.
Beatrice O., 68, who keeps three beehives behind her garage and scheduled her hysterectomy around the honey harvest. The disagreement is whether combining two real, separately-positive trials' drugs is sound extrapolation or two results that were never actually shown to add up.
Yolanda P., 71, who sold her home of forty years and moved near her daughter three months before her diagnosis. The disagreement is what an equivocal HER2 result is allowed to mean when the trial behind the drug tested only clearly positive patients.
Jenna T., engaged with no wedding date set until she knew what she was dealing with, newly an aunt the same month as her diagnosis. The disagreement is how honestly to frame a fertility-sparing option's real regression and relapse numbers against the clock she's already watching.
Marisol A. and her husband, three IVF cycles into treatment for unexplained infertility when a sister's breast cancer diagnosis led to genetic testing that changed everything. The disagreement is what a guideline age window actually owes a patient whose fertility clock isn't following it.
Priyanka D., 27, a dental hygienist who went back to work eleven weeks after a molar pregnancy rather than sit at home checking an app for her next hCG result. The disagreement is whether one striking number should override a validated composite score built to be read as a whole.